Zhenhua Wu

20090181911, Jul 16, 2009

Aug 3, 2006

11/988999

Benslav V. Zlokovic - Rochester NY, US
Zhenhua Wu - Wellesley MA, US
Rashid Deane - Rochester NY, US

A61K 31/7088
C12N 15/87
C12Q 1/68
C12N 15/86
C12N 15/88

514 44, 435455, 435 6, 435456, 435458

Neurovascular disorder critically contributes to the development and pathogenesis of Alzheimer's disease (AD). Transcriptional profiling of human brain endothelial cells (BEC) defines a subset of age-independent genes significantly altered in AD including the homebox gene GAX whose expression controls vascular phenotype and is low in AD. By using viral-mediated GAX gene silencing and transfer, restoring GAX expression in AD BEC is angio-genic, transcriptionally suppresses the AFX1 forkhead transcription factor-mediated apoptosis, and increases the levels of a major amyloid β-peptide (Aβ) clearance receptor, the low density lipoprotein receptor-related protein 1 (LRP-1) at the blood-brain barrier. In a mouse model of Alzheimer's disease, deletion of the Gax gene results in reductions in brain capillary density and the resting cerebral blood flow, loss of angiogenic brain response to hypoxia, and an impaired Aβ brain efflux caused by reduced LRP-1 levels. The link of GAX gene to AD neurovascular dysfunction provides new mechanistic and therapeutic insights into AD.

20220380352, Dec 1, 2022

May 3, 2022

17/661909

- Tokyo, JP
Silvia BUONAMICI - Boston, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Belmont MA, US
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong XIAO - Belmont MA, US

C07D 405/12
A61P 35/00
A61K 47/68
A61K 47/60
A61K 9/127
A61K 9/51
A61K 31/365
A61K 31/496
A61K 39/00
A61K 39/395
A61K 45/06
C07D 313/00
C07D 405/06
C07K 16/24
C07K 16/28
C07K 16/30
C07K 16/32
C07K 16/40
C12Q 1/6886
G01N 33/50
G01N 33/574

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

20210299269, Sep 30, 2021

May 31, 2019

17/059635

- TOKYO, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Tbilisi, GE
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong Xiao - Belmont MA, US

A61K 47/68
C07K 16/32
C07K 16/28
C07K 16/40
A61K 47/60
C07D 405/06
A61P 35/00
G01N 33/50
C07D 313/00
A61K 31/496
A61K 31/365
A61K 39/395
A61K 45/06
A61K 39/00
A61K 9/127
A61K 9/51
C12Q 1/6886
G01N 33/574
C07K 16/30
C07K 16/24

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

20210101888, Apr 8, 2021

Nov 30, 2020

17/247117

- Tokyo, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Belmont MA, US
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong XIAO - Belmont MA, US

C07D 405/12
A61P 35/00

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.